Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients
- 8 February 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (7) , 2012-2022
Abstract
Purpose Fibroblast-activated protein (FAP) is highly expressed in cancer-associated fibroblasts (CAFs) of many solid cancers, but low or absent in normal tissues. Our study aimed to develop a novel FAP-specific tracer, namely [18F]FAP-2286, and evaluated its performance in comparison with well-established agents such as [18F]FAPI-42 and [68Ga]Ga-FAP-2286 in preclinical research, as well as 2-[18F]FDG in pilot clinical study. Methods [18F]FAP-2286 was manually synthesized in accordance with Good Manufacturing Practice (GMP). Subsequent investigations encompassed cell uptake, competitive binding affinity, internalization and efflux assays using HT-1080hFAP cell lines. PET imaging and biodistribution studies were conducted in HEK-293ThFAP, A549hFAP, HT-1080hFAP tumor-bearing mice as well as HEK-293T, A549 and HT-1080 control groups. Furthermore, clinical evaluation of [18F]FAP-2286 was performed in fifteen patients with various cancers compared to 2-[18F]FDG PET. Results The radiolabeling yield of [18F]FAP-2286 was 30.53 ± 5.20%, with a radiochemical purity exceeding 97%. In cell assays, [18F]FAP-2286 showed specific uptake, high internalization fraction and low cellular efflux. Rapid tumor uptake and satisfactory tumor retention was observed on micro-PET imaging and cancer patients. Meanwhile, the clinical research demonstrated that [18F]FAP-2286 may represent an alternative for low glucose-metabolism malignant tumors PET imaging such as gastric cancers. Conclusion [18F]FAP-2286 showed superior imaging quality including rapid and high target uptake and satisfactory retention in both tumor-bearing mice and cancer patients. It may emerge as a promising candidate for early or delayed phase imaging and 2-[18F]FDG non-avid cancers PET scan.Keywords
Funding Information
- National Natural Science Foundation of China (No.81901772, No.82001879)
- Natural Science Foundation of Guangdong Province (No.2019A1515011893, 2023A1515011300)
- Basic and Applied Basic Research Foundation of Guangdong Province (No. 2020A1515110159)
- Science and Technology Project of Guangzhou City (No. 202102010354)
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia&The First People’s Hospital of Kashi Fund (No.SKL-HIDCA-2020-KS2)
- Zhong Nanshan Medical Foundation of Guangdong Province (ZNSA-2020003)
This publication has 30 references indexed in Scilit:
- In search of definitions: Cancer‐associated fibroblasts and their markersInternational Journal of Cancer, 2019
- Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation ProteinJournal of Nuclear Medicine, 2018
- Recent Advances in 18F Radiochemistry: A Focus on B-18F, Si-18F, Al-18F, and C-18F Radiofluorination via Spirocyclic Iodonium YlidesJournal of Nuclear Medicine, 2017
- Impact of host cell line choice on glycan profileCritical Reviews in Biotechnology, 2017
- Gallium-68 in Medical ImagingCurrent Radiopharmaceuticals, 2016
- The biology and function of fibroblasts in cancerNature Reviews Cancer, 2016
- Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitroAdvances in Medical Sciences, 2015
- The Role of 18F-FDG PET/CT in the Primary Staging of Gastric CancerMolecular Imaging and Radionuclide Therapy, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update